Exploring VEGFR2 as a Novel Target for Kidney Renal Clear Cell Carcinoma and Molecular Docking-Based Screening of Garcinia Oblongifolia Compounds

The increasing global cancer burden highlights the urgent need for effective cancer control strategies, particularly for aggressive types like Kidney Renal Clear Cell Carcinoma (KIRC). This study explores the potential of Garcinia oblongifolia compounds as targeted inhibitors of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2), a key player in tumor angiogenesis, using in silico approach for KIRC using computational approaches to assess their pharmacokinetic properties, toxicity profiles, and binding interactions. The role of VEGFR2 in cancer progression and its correlated genes were identified. A combination of ADMET profiling, bioactivity assessment, and molecular docking was utilized to screen the druglike compounds from G. oblongifolia. The study identifies three potential VEGFR2 inhibitors exhibiting a strong pharmacokinetic profile, binding affinity, and moderate bioactivity. The most promising compounds identified from G. oblongifolia are PubChem IDs: 11559542, 5280961, and 5281656 as promising VEGFR2 inhibitors with favorable docking energies and interactions with critical residues, including the DFG motif. Docking studies showed that 11559542's Pi-Anion interaction with ASP1046 stabilizes the DFG-out conformation, like Axitinib's hydrogen bonding. Compound PubChem ID:11559542 from G. oblongifolia, shows promising electrostatic interactions and moderate bioactivity, therefore, it can be considered a prime candidate for optimization to inhibit VEGFR2. The study supports targeted cancer therapy with natural product derivatives. However, in vitro and in vivo validation may be required in future studies. 

Keywords: VEGFR2, G. oblongifolia, Axitinib, Molecular Docking, ADMET, Cancer Therapy, Drug-Likeness, Bioactivity, Targeted Inhibition.

[1] F. Bray et al., "Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries," CA: A Cancer Journal for Clinicians, vol. 74, no. 3, pp. 229-263, 2024.

[2] M. McTigue, B. W. Murray, J. H. Chen, Y. L. Deng, J. Solowiej, and R. S. Kania, "Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors," Proc Natl Acad Sci U S A, vol. 109, no. 45, pp. 18281-9, Nov 6 2012.

[3] E. Jonasch, C. L. Walker, and W. K. Rathmell, "Clear cell renal cell carcinoma ontogeny and mechanisms of lethality," Nature Reviews Nephrology, vol. 17, no. 4, pp. 245-261, 2021.

[4] (2024, 12 November, 2024). Kidney cancer statistics. Available: https://www.wcrf.org/cancer-trends/kidney-cancer-statistics/

[5] A. Alasker et al., "Exploring Renal Malignancies in Saudi Arabia: Insights from a Tertiary Care Center Study," Journal of Kidney Cancer and VHL, pp. 13-19, 12/21 2023.

[6] N. Ferrara, "VEGF and the quest for tumour angiogenesis factors," Nature Reviews Cancer, vol. 2, no. 10, pp. 795-803, 2002/10/01 2002.

[7] K. Holmes, O. L. Roberts, A. M. Thomas, and M. J. Cross, "Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition," Cell Signal, vol. 19, no. 10, pp. 2003-12, Oct 2007.

[8] Z.-L. Liu, H.-H. Chen, L.-L. Zheng, L.-P. Sun, and L. Shi, "Angiogenic signaling pathways and anti-angiogenic therapy for cancer," Signal Transduction and Targeted Therapy, vol. 8, no. 1, p. 198, 2023/05/11 2023.

[9] L. Perez-Gutierrez and N. Ferrara, "Biology and therapeutic targeting of vascular endothelial growth factor A," Nat Rev Mol Cell Biol, vol. 24, no. 11, pp. 816-834, Nov 2023.

[10] P. Carmeliet and R. K. Jain, "Molecular mechanisms and clinical applications of angiogenesis," Nature, vol. 473, no. 7347, pp. 298-307, May 19 2011.

[11] K. R. Molhoek et al., "VEGFR-2 expression in human melanoma: revised assessment," Int J Cancer, vol. 129, no. 12, pp. 2807-15, Dec 15 2011.

[12] D. Sia, C. Alsinet, P. Newell, and A. Villanueva, "VEGF signaling in cancer treatment," Curr Pharm Des, vol. 20, no. 17, pp. 2834-42, 2014.

[13] M. Gross-Goupil, L. Francois, A. Quivy, and A. Ravaud, "Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinoma," Clin Med Insights Oncol, vol. 7, pp. 269-77, Oct 29 2013.

[14] S. Shyam Sunder, U. C. Sharma, and S. Pokharel, "Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management," Signal Transduct Target Ther, vol. 8, no. 1, p. 262, Jul 7 2023.

[15] W. G. Shan, T. S. Lin, H. N. Yu, Y. Chen, and Z. J. Zhan, "Polyprenylated Xanthones and Benzophenones from the Bark of Garcinia oblongifolia," Helvetica Chimica Acta, vol. 95, 08/01 2012.

[16] K. S. Triyasa, A. Diantini, and M. I. Barliana, "A Review of Herbal Medicine-Based Phytochemical of Garcinia as Molecular Therapy for Breast Cancer," Drug Des Devel Ther, vol. 16, pp. 3573-3588, 2022.

[17] R. P. Hertzberg, M. J. Caranfa, and S. M. Hecht, "On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex," Biochemistry, vol. 28, no. 11, pp. 4629-4638, 1989.

[18] H. O. Fearnhead, M. Chwalinski, R. T. Snowden, M. G. Ormerod, and G. M. Cohen, "Dexamethasone and etoposide induce apoptosis in rat thymocytes from different phases of the cell cycle," Biochemical pharmacology, vol. 48, no. 6, pp. 1073-1079, 1994.

[19] P. Li et al., "Comparative UPLC-QTOF-MS-based metabolomics and bioactivities analyses of Garcinia oblongifolia," Journal of Chromatography B, vol. 1011, pp. 179-195, 2016.

[20] D. Brawand et al., "The evolution of gene expression levels in mammalian organs," Nature, vol. 478, no. 7369, pp. 343-348, 2011/10/01 2011.

[21] Z. Tang, B. Kang, C. Li, T. Chen, and Z. Zhang, "GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis," Nucleic acids research, vol. 47, no. W1, pp. W556-W560, 2019.

[22] K. Tomczak, P. Czerwi?ska, and M. Wiznerowicz, "Review The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge," Contemporary Oncology/Wsp??czesna Onkologia, vol. 2015, no. 1, pp. 68-77, 2015.

[23] J. Lonsdale et al., "The genotype-tissue expression (GTEx) project," Nature genetics, vol. 45, no. 6, pp. 580-585, 2013.

[24] D. S. Chandrashekar et al., "UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses," Neoplasia, vol. 19, no. 8, pp. 649-658, 2017.

[25] J. Koster, R. Volckmann, D. Zwijnenburg, P. Molenaar, and R. Versteeg, "R2: Genomics analysis and visualization platform," Cancer Research, vol. 79, no. 13_Supplement, pp. 2490-2490, 2019.

[26] D. Szklarczyk et al., "The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets," Nucleic acids research, vol. 49, no. D1, pp. D605-D612, 2021.

[27] X. Yin et al., "CODD-Pred: A Web Server for Efficient Target Identification and Bioactivity Prediction of Small Molecules," Journal of Chemical Information and Modeling, vol. 63, no. 20, pp. 6169-6176, 2023.

[28] K.-C. Hsu, Y.-F. Chen, S.-R. Lin, and J.-M. Yang, "iGEMDOCK: a graphical environment of enhancing GEMDOCK using pharmacological interactions and post-screening analysis," BMC Bioinformatics, vol. 12, no. 1, p. S33, 2011/02/15 2011.

[29] M. Shibuya, "Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies," Genes Cancer, vol. 2, no. 12, pp. 1097-105, Dec 2011.

[30] C. S. Abhinand, R. Raju, S. J. Soumya, P. S. Arya, and P. R. Sudhakaran, "VEGF-A/VEGFR2 signaling network in endothelial cells relevant to angiogenesis," J Cell Commun Signal, vol. 10, no. 4, pp. 347-354, Dec 2016.

[31] S. Kdimati, C. S. Mullins, and M. Linnebacher, "Cancer-Cell-Derived IgG and Its Potential Role in Tumor Development," Int J Mol Sci, vol. 22, no. 21, Oct 27 2021.

[32] J. Ma et al., "Signaling pathways in vascular function and hypertension: molecular mechanisms and therapeutic interventions," Signal Transduction and Targeted Therapy, vol. 8, no. 1, p. 168, 2023/04/20 2023.

[33] Y. Yang and Y. Cao, "The impact of VEGF on cancer metastasis and systemic disease," Seminars in Cancer Biology, vol. 86, pp. 251-261, 2022/11/01/ 2022.

[34] T. R. Holzer et al., "Tumor cell expression of vascular endothelial growth factor receptor 2 is an adverse prognostic factor in patients with squamous cell carcinoma of the lung," PLoS One, vol. 8, no. 11, p. e80292, 2013.

[35] R. S. Kania, "Structure?Based Design and Characterization of Axitinib," Kinase inhibitor drugs, pp. 167-201, 2009.